| Original language | English |
|---|---|
| Pages (from-to) | 660-661 |
| Number of pages | 2 |
| Journal | Lancet Neurology |
| Volume | 11 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2012 |
Cite this
@article{a4772d842eac4855985e98e5c04d455b,
title = "Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA? Reply",
author = "Hankey, {Graeme J.}",
year = "2012",
month = "8",
doi = "10.1016/S1474-4422(12)70157-6",
language = "English",
volume = "11",
pages = "660--661",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Academic Press",
number = "8",
}
Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA? Reply. / Hankey, Graeme J.
In: Lancet Neurology, Vol. 11, No. 8, 08.2012, p. 660-661.Research output: Contribution to journal › Letter
TY - JOUR
T1 - Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA? Reply
AU - Hankey, Graeme J.
PY - 2012/8
Y1 - 2012/8
U2 - 10.1016/S1474-4422(12)70157-6
DO - 10.1016/S1474-4422(12)70157-6
M3 - Letter
VL - 11
SP - 660
EP - 661
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 8
ER -